Arthur Cox advises Re-Vana Therapeutics on Series A Fund Round
Arthur Cox has advised Re-Vana Therapeutics as it successfully raised $11.9 million in a Series A funding round. The investment proceeds, among the largest ever to be secured by a Northern Ireland based company, represented an oversubscription of $4m.
Re-Vana Therapeutics, a spinout from Queen’s University Belfast is a specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases.
The financing was led by Visionary Ventures with additional investors including ExSight Ventures, InFocus Capital Partners, Qubis Ltd, Co-Fund NI and TechStart Ventures.
The funding will allow Re-Vana to further develop its ground-breaking technologies that have the potential to enable sustained office-based drug delivery without surgery to treat ocular disease.